GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Accounts Payable

4basebio (XTER:88Q) Accounts Payable : €0.62 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Accounts Payable?

4basebio's Accounts Payable for the quarter that ended in Jun. 2023 was €0.62 Mil.

4basebio's quarterly Accounts Payable declined from Jun. 2022 (€0.77 Mil) to Dec. 2022 (€0.56 Mil) but then increased from Dec. 2022 (€0.56 Mil) to Jun. 2023 (€0.62 Mil).

4basebio's annual Accounts Payable increased from Dec. 2020 (€0.11 Mil) to Dec. 2021 (€0.42 Mil) and increased from Dec. 2021 (€0.42 Mil) to Dec. 2022 (€0.56 Mil).


4basebio Accounts Payable Historical Data

The historical data trend for 4basebio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Accounts Payable Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Accounts Payable
0.12 0.11 0.42 0.56

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Accounts Payable Get a 7-Day Free Trial 0.18 0.42 0.77 0.56 0.62

4basebio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


4basebio Accounts Payable Related Terms

Thank you for viewing the detailed overview of 4basebio's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


4basebio (XTER:88Q) Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines